Home
Search
Collections
Journals
About
Contact us
My IOPscience
Markers of pancreatic function in the breath
This content has been downloaded from IOPscience. Please scroll down to see the full text. 2014 J. Breath Res. 8 046009 (http://iopscience.iop.org/1752-7163/8/4/046009) View the table of contents for this issue, or go to the journal homepage for more
Download details: IP Address: 202.28.191.34 This content was downloaded on 25/02/2015 at 04:01
Please note that terms and conditions apply.
Journal of Breath Research J. Breath Res. 8 (2014) 046009 (6pp)
doi:10.1088/1752-7155/8/4/046009
Markers of pancreatic function in the breath Kiera Roberts1, Ivan Liu 1, Adam Jaffe1,2, Charles F Verge1,3 and Paul S Thomas1,4 1
Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Australia Department of Respiratory Medicine, Sydney Children’s Hospital, Randwick, NSW 2031, Australia 3 Department of Endocrinology, Sydney Children’s Hospital, Randwick, NSW 2031, Australia 4 Department of Respiratory Medicine, Prince of Wales Hospital, Randwick, NSW 2031, Australia 2
E-mail: [email protected] Received 18 July 2014, revised 13 October 2014 Accepted for publication 30 October 2014 Published 24 November 2014 Abstract
Exhaled breath analysis is able to identify biomarkers of respiratory and systemic diseases. It was hypothesized that markers of pancreatic function would be identified in the breath of those with diabetes mellitus and cystic fibrosis. Children aged 6–18 years old with diabetes mellitus (DM), cystic fibrosis (CF), cystic fibrosis related diabetes (CFRD) and healthy controls (C) contributed exhaled breath condensate (EBC), with concurrent blood glucose measurements taken from a subset. EBC C-peptide, glucose, sodium concentrations and conductivity were subsequently measured. A total of 104 children were recruited (DM = 56, CF = 26, CFRD = 5, C = 17). C-peptide was detected in EBC: CF 19.6 ± 11.7 pmol L−1; DM: 9.66 ± 8.27 pmol L−1; CFRD: 11.9 ± 9.23 pmol L−1 which was significantly higher than in the control group (0.987 ± 2.26 pmol L−1) (p
Search
Collections
Journals
About
Contact us
My IOPscience
Markers of pancreatic function in the breath
This content has been downloaded from IOPscience. Please scroll down to see the full text. 2014 J. Breath Res. 8 046009 (http://iopscience.iop.org/1752-7163/8/4/046009) View the table of contents for this issue, or go to the journal homepage for more
Download details: IP Address: 202.28.191.34 This content was downloaded on 25/02/2015 at 04:01
Please note that terms and conditions apply.
Journal of Breath Research J. Breath Res. 8 (2014) 046009 (6pp)
doi:10.1088/1752-7155/8/4/046009
Markers of pancreatic function in the breath Kiera Roberts1, Ivan Liu 1, Adam Jaffe1,2, Charles F Verge1,3 and Paul S Thomas1,4 1
Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Australia Department of Respiratory Medicine, Sydney Children’s Hospital, Randwick, NSW 2031, Australia 3 Department of Endocrinology, Sydney Children’s Hospital, Randwick, NSW 2031, Australia 4 Department of Respiratory Medicine, Prince of Wales Hospital, Randwick, NSW 2031, Australia 2
E-mail: [email protected] Received 18 July 2014, revised 13 October 2014 Accepted for publication 30 October 2014 Published 24 November 2014 Abstract
Exhaled breath analysis is able to identify biomarkers of respiratory and systemic diseases. It was hypothesized that markers of pancreatic function would be identified in the breath of those with diabetes mellitus and cystic fibrosis. Children aged 6–18 years old with diabetes mellitus (DM), cystic fibrosis (CF), cystic fibrosis related diabetes (CFRD) and healthy controls (C) contributed exhaled breath condensate (EBC), with concurrent blood glucose measurements taken from a subset. EBC C-peptide, glucose, sodium concentrations and conductivity were subsequently measured. A total of 104 children were recruited (DM = 56, CF = 26, CFRD = 5, C = 17). C-peptide was detected in EBC: CF 19.6 ± 11.7 pmol L−1; DM: 9.66 ± 8.27 pmol L−1; CFRD: 11.9 ± 9.23 pmol L−1 which was significantly higher than in the control group (0.987 ± 2.26 pmol L−1) (p
